Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07689175 · ClinicalTrials.gov registry record · Phase 2
Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma
A Phase 2 study, sponsored by University of Texas Southwestern Medical Center.
- Not yet
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT07689175: Clinical Trial Phase 2 study, sponsored by University of Texas Southwestern Medical Center.
NCT07689175 is a Phase 2 study that has not yet begun recruiting, run by University of Texas Southwestern Medical Center. The registered enrollment target is 60 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07689175, a Phase 2 study, has not yet begun recruiting, sponsored by University of Texas Southwestern Medical Center.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if immunotherapy including nivolumab plus ipilimumab is effective and safe in treating hepatocellular carcinoma.
Primary Outcome
To determine the proportion of patients with imaging evidence of subsequent disease control (stable disease, partial response, or complete response); Per RECIST v.1.1. among subjects who attained an initial favorable imaging response.
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab (3 mg/kg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-10-31 |
| Est. Completion | 2032-10-31 |
| Phase | Phase 2 |
What is known before NCT07689175 opens enrollment
NCT07689175 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT07689175 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07689175 about?
NCT07689175 is a clinical study titled "Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma". The goal of this clinical trial is to learn if immunotherapy including nivolumab plus ipilimumab is effective and safe in treating hepatocellular carcinoma.
What is the current status of trial NCT07689175?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2026-10-31. Estimated completion is 2032-10-31.
What interventions are being tested in trial NCT07689175?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (3 mg/kg) (DRUG).
Who is sponsoring clinical trial NCT07689175?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07689175's enrollment target sits among peer trials
60 1027th of 2000 higher than 868 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI